I agree. I try to take advantage of swing trades too ,but with Gild its tough to predict how this thing will go short term.
key word "trading". Start investing in GILD and you might have a change of heart. Its returned 50% plus a year for 3 straight years.
Totally wrong . Analysts are typically barred from trading names they cover. Sure- you can assume some do it anyway or have family accounts and leak names to family/friends, but I know several that actually take the rule seriously. This stock is heavily manipulated and the market is basically yawning at everything until we get closer to having a product approved.
And what did you do- buy your wife a new refrigerator with the 5k you made? Some dont care about making a few thousand bucks. I'm trying to change my life, not maintain a middle class lifestyle. That requires risk and I like my chances here.
at this point- mgmt is just doing what they can to stay afloat and justify a salary for a few more years. Getting bought out would have meant losing a job so they did the selfish and predictable thing of acquiring a name to give false hope and continue this sheet show downward on another low patient/no room for error on execution drug mission. Not going to work. I'm selling in december, taking a 65k+ loss. Not the worse thing in the 39% bracket ,but still not as fun as making 65k on a trade.
they must have been better about turning the lights off after work this quarter. Maybe installed some more efficient light bulbs too. Both Work. (just having a little fun :) )
this stock is too all over the place to play options in my opinion. Better to hold common stock and take time out of the equation
where is the secondary offering u were talking about? Better yet- how does a company with no product sales beat on revs? Get a clue
Agreed on the buy the dip mentality. I have a core(2.80 buy in), but also have made money on swing trades on this name. After the last drop to $3.75-4.00 I doubled down and now am paranoid about taking profits because I'm nervous that I won't get another shot to get in at those levels. If it does- I'll buy more, but I'm extremely confident in this company and its chances of carrying out its goals. I'm still young so if I'm wrong fine- I have time to recover.
After listening to the ER call, you see the company is executing according to schedule, but as always without flair or pump articles like many small bios. There is a personality to this company that sets it apart from other small bios. There is little wasted effort trying to draw a following, and its a quiet confidence that essentially says smart money will know what we are on they cusp of doing here, and if you can't recognize it fine we don't care about recruiting you. This is totally opposite of many small bios like INO/ KERX/ MNKD/GALE and other small bios that are riddled with ignorant retail investors playing the pump and dump catalyst game praying they have a winner in their portfolio, and who don't know anything about actual value other than day to day price action.
As of now, its incredibly exciting to see our RSV phase trial process coming together and being give or take a year away from what will be a critical event for this company- phase II results for RSV and particularly pregnant women. A positive phase trial report next fall will essentially de-risk our RSV vaccine in terms of the regulatory challenges of getting it to market, and with that de-risked situation comes an untapped several billion dollar market with no competitors in sight for several years in our indication areas.
Ebola and a fast tracked H7N9 provide unexpected near term talking points and the potential to obtain some revenue in the event a stockpile order is placed. Not to mention they validate our VLP platform.
The company is executing and doing so in classic nvax fashion. U rarely hear Stan or mgmt overspeak because they don't have to. Our science has spoken for itself thus far. Very exciting year coming up-cheers
lol- so the company fixed reimbursement issues with brazil in one week? Or are we getting over your head now in talking about this topic....
no- since I am in my late 20's its not the type of investment vehicle for a person of my age, but if you don't like manipulation and the risk of equities there are always more conservative investment options. That's my point
with ebola comes ignorant swing traders. RSV isn't sexy like ebola so won't get much love from retail traders trying to make a quick buck.
yes- but that isn' going to be baked into last Quater's earnings. That is a future source of potential funds from governmental organizations if and when our vaccine is bought up by governments down the road.
Question- what product are you relying on for even considering the ER a meaningful event financially speaking? Guidance and timeline updates are the only value coming from this ER.
Earnings have never been a price driver for this stock- obviously because we don't have a product on the market. Sure- you can be like every other smal bio retail investor and pray a meaningful tid-bit comes out or god forbid A PARTNERSHIP during the conference call- but that is just blind guesses in the dark people naturally think about to find an excuse to get excited about the report. An update on the timetable for our ongoing projects will be nice and thats the extent of what I expect to hear about.